Dataset from A Randomised Open Label Multi-centre Trial to Evaluate the Pharmacokinetic, Efficacy and Safety Parameters of Nevirapine 150mg/m2 and Nevirapine 4 or 7 mg/kg When Administered in Combination With AZT and 3TC for 48 Weeks in Antiretroviral naïve Paediatric Patients.

Trial to evaluate steady state pharmacokinetic parameters of nevirapine 150mg/m2 and nevirapine 4 or 7 mg/kg after 4 weeks, and efficacy and safety of the dosing when administered for 48 weeks in antiretroviral drug naïve paediatric patients.

本试验旨在评估抗逆转录病毒药物初治儿科患者中，每平方米体表面积150毫克奈韦拉平（nevirapine）与每公斤体重4或7毫克奈韦拉平这两种给药方案，连续给药4周后的稳态药代动力学参数，以及该方案持续给药48周时的有效性与安全性。